WO2013025064A3 - Ｗｎｔ 유인 수용체를 포함하는 항암 조성물 - Google Patents

Ｗｎｔ 유인 수용체를 포함하는 항암 조성물 Download PDF

Info

Publication number
WO2013025064A3
WO2013025064A3 PCT/KR2012/006527 KR2012006527W WO2013025064A3 WO 2013025064 A3 WO2013025064 A3 WO 2013025064A3 KR 2012006527 W KR2012006527 W KR 2012006527W WO 2013025064 A3 WO2013025064 A3 WO 2013025064A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
composition
wnt
decoy receptors
cancer composition
Prior art date
Application number
PCT/KR2012/006527
Other languages
English (en)
French (fr)
Other versions
WO2013025064A2 (ko
Inventor
윤채옥
이정선
Original Assignee
Yun Chae Ok
Lee Jung-Sun
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yun Chae Ok, Lee Jung-Sun filed Critical Yun Chae Ok
Priority to US14/239,259 priority Critical patent/US9657069B2/en
Priority to CN201280040178.8A priority patent/CN103764161B/zh
Priority to EP12824372.2A priority patent/EP2745842B1/en
Publication of WO2013025064A2 publication Critical patent/WO2013025064A2/ko
Publication of WO2013025064A3 publication Critical patent/WO2013025064A3/ko
Priority to US15/494,211 priority patent/US9920099B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

본 발명은 Wnt 유인 수용체를 유효성분으로 포함하는 암의 예방 또는 치료용 조성물에 관한 것이다 본 발명의 조성물 또는 이의 발현 산물은 Wnt 리간드에 결합하여 리간드-수용체 상호작용을 차단함으로써 암의 발생, 성장, 증식 및 전이를 억제하고 암세포의 사멸을 유도함으로써 효율적인 항암 조성물로 유용하게 이용될 수 있다.
PCT/KR2012/006527 2011-08-18 2012-08-16 Ｗｎｔ 유인 수용체를 포함하는 항암 조성물 WO2013025064A2 (ko)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US14/239,259 US9657069B2 (en) 2011-08-18 2012-08-16 Anti-cancer compositions containing WNT decoy receptor
CN201280040178.8A CN103764161B (zh) 2011-08-18 2012-08-16 包含Wnt 诱因受体的抗癌组合物
EP12824372.2A EP2745842B1 (en) 2011-08-18 2012-08-16 Anti-cancer composition comprising wnt decoy receptors
US15/494,211 US9920099B2 (en) 2011-08-18 2017-04-21 Anti-cancer compositions containing Wnt decoy receptor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020110082087A KR101399062B1 (ko) 2011-08-18 2011-08-18 Ｗｎｔ 유인 수용체를 포함하는 항암 조성물
KR10-2011-0082087 2011-08-18

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US14/239,259 A-371-Of-International US9657069B2 (en) 2011-08-18 2012-08-16 Anti-cancer compositions containing WNT decoy receptor
US15/494,211 Division US9920099B2 (en) 2011-08-18 2017-04-21 Anti-cancer compositions containing Wnt decoy receptor

Publications (2)

Publication Number Publication Date
WO2013025064A2 WO2013025064A2 (ko) 2013-02-21
WO2013025064A3 true WO2013025064A3 (ko) 2013-06-13

Family

ID=47715607

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/006527 WO2013025064A2 (ko) 2011-08-18 2012-08-16 Ｗｎｔ 유인 수용체를 포함하는 항암 조성물

Country Status (5)

Country Link
US (2) US9657069B2 (ko)
EP (1) EP2745842B1 (ko)
KR (1) KR101399062B1 (ko)
CN (1) CN103764161B (ko)
WO (1) WO2013025064A2 (ko)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108289920A (zh) * 2015-10-12 2018-07-17 汉阳大学校产学协力团 用于基因转移和基因治疗的腺病毒复合物
US11564954B2 (en) * 2019-02-22 2023-01-31 Arizona Board Of Regents On Behalf Of Arizona State University Tumor-delivered multi-target therapeutics for colon cancer
WO2020172461A1 (en) * 2019-02-22 2020-08-27 Arizona Board Of Regents On Behalf Of Arizona State University Using tumor-navigating salmonella to modulate tumor metabolism

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
JPWO2006077824A1 (ja) * 2005-01-18 2008-08-07 国立大学法人京都大学 神経細胞再生のための医薬
WO2007142987A2 (en) * 2006-05-30 2007-12-13 Wisconsin Alumni Research Foundation Mammary stem cell marker
KR100807069B1 (ko) * 2007-09-21 2008-02-25 고려대학교 산학협력단 암 치료용 의약 조성물
KR20100091170A (ko) * 2007-11-02 2010-08-18 노파르티스 아게 저밀도-지단백질 수용체-관련 단백질 ６ (ｌｒｐ６)을 조정하기 위한 분자 및 방법
TWI535445B (zh) * 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AKIRI, G. ET AL.: "Wnt pathway aberrations including autocrine Wnt activation occur at high frequency in human non-small-cell lung carcinoma", ONCOGENE, vol. 28, no. 21, 2009, pages 2163 - 2172, XP055071213 *
LIU, C-C. ET AL.: "Cooperative Folding and Ligand-binding Properties of LRP6 beta- Propeller Domains", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 284, no. 22, 2009, pages 15299 - 15307, XP055145560 *
RUSSELL, W. C. ET AL.: "Update on adenovirus and its vectors", JOURNAL OF GENERAL VIROLOGY, vol. 81, 2000, pages 2573 - 2604, XP002247418 *

Also Published As

Publication number Publication date
US9920099B2 (en) 2018-03-20
US20140315825A1 (en) 2014-10-23
EP2745842A2 (en) 2014-06-25
EP2745842B1 (en) 2018-01-17
EP2745842A4 (en) 2015-05-27
KR20130019847A (ko) 2013-02-27
CN103764161B (zh) 2015-09-02
US20170275340A1 (en) 2017-09-28
WO2013025064A2 (ko) 2013-02-21
KR101399062B1 (ko) 2014-05-27
CN103764161A (zh) 2014-04-30
US9657069B2 (en) 2017-05-23

Similar Documents

Publication Publication Date Title
PH12019502809A1 (en) Substituted tricyclic compounds as fgfr inhibitors
EP2721033A4 (en) COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE AS IDH1 MUTANT INHIBITORS FOR THE TREATMENT OF CANCER
MX2022005200A (es) Composiciones y metodos para modular la expresion de angiotensinogeno.
EA201500582A1 (ru) Тройные фунгицидные смеси
NZ628294A (en) Compositions and methods of use of phorbol esters for the treatment of stroke
EP2678320A4 (en) FLUMAZENIL COMPLEXES, COMPOSITIONS THEREOF AND USES THEREOF
EP2732429A4 (en) COMMON CONTENT OF SOCIAL NETWORKS
WO2012033525A3 (en) P53-mdm2 antagonists
MX2014001218A (es) Tratamiento de cancer de mama.
MX2014006136A (es) Uso de aril- y hetarilcarboxamidas como endoparasiticidas.
WO2013023084A3 (en) Methods and compositions for inhibiting the growth and/or proliferation of myc-driven tumor cells
EP2649033A4 (en) COMPOSITIONS AND METHODS FOR STABILIZING INGREDIENTS USING 2,4-PENTANEDIONES COMPOUNDS
MX2014005721A (es) 2-tiopirimidinonas.
WO2012177935A8 (en) Compositions and methods for the treatment of cancer
IL231569A0 (en) Treated fillings, their preparations that include them and objects made from them
MX2017011299A (es) Material para envasado que comprende composicion antimicrobiana.
WO2013134407A3 (en) Procaspase 3 activation by combination therapy
MX350970B (es) Métodos y composiciones para extender la vida útil en depósito de productos de plantas.
WO2013034989A3 (en) Microrna-based methods and assays for osteosarcoma
MX359670B (es) Proceso para preparar productos que comprenden activos estabilizados y composiciones que los comprenden.
WO2013025064A3 (ko) Ｗｎｔ 유인 수용체를 포함하는 항암 조성물
WO2014028939A3 (en) Targeting phosphofructokinase and its glycosylation form for cancer
EP2910246A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF CANCER WITH ENOBLOCK AS AN ACTIVE SUBSTANCE
WO2011103028A3 (en) Compositions and methods for inhibiting mmset
SG178967A1 (en) Antimicrobial compositions and products

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12824372

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 14239259

Country of ref document: US